产品
编 号：F454504
分子式：C43H61N9O9S
分子量：880.06
分子式：C43H61N9O9S
分子量：880.06
产品类型
规格
价格
是否有货
结构图
CAS No: 77128-69-9
产品详情
生物活性：
[Glp5,(Me)Phe8,Sar9] Substance P (5-11) (DiMe-C7) is a Substance P (HY-P0201) analogue that has approximately the same effects as Substance P (HY-P0201) on neurokinin 1 receptor (NK1R) in rat brain, but with a much longer duration of action. [Glp5,(Me)Phe8,Sar9] Substance P (5-11) selectively activates dopamine metabolism in the mesencephalon and midbrain cortex of the rat brain. [Glp5,(Me)Phe8,Sar9] Substance P (5-11) also increases motor activity and induces recovery of addictive agent-seeking behavior in rats.
体内研究：
[Glp5, (Me)Phe8,Sar9] Substance P (5-11) (注入腹侧被盖区；2 μg/侧；单次) 选择性地激活大鼠大脑间脑和中脑皮层的多巴胺代谢。[Glp5, (Me)Phe8,Sar9] Substance P (5-11) (注入腹侧被盖区；0.5、1.5、3 μg/侧；单次) 增加大鼠运动活性，诱导成瘾剂寻求行为的恢复。Animal Model:Male Sprague-Dawley rats (300-350 g).
Dosage:2 μg/side
Administration:Inject into the ventral tegmental area; single
Result:Selectively activated mesolimbic and mesocortical dopamine metabolism.
Animal Model:Male Wistar rats (300-350 g).
Dosage:0.5, 1.5, 3 μg/side
Administration:Inject into the ventral tegmental area; single
Result:Significantly increased locomotor activity when at 3 μg/side.
[Glp5,(Me)Phe8,Sar9] Substance P (5-11) (DiMe-C7) is a Substance P (HY-P0201) analogue that has approximately the same effects as Substance P (HY-P0201) on neurokinin 1 receptor (NK1R) in rat brain, but with a much longer duration of action. [Glp5,(Me)Phe8,Sar9] Substance P (5-11) selectively activates dopamine metabolism in the mesencephalon and midbrain cortex of the rat brain. [Glp5,(Me)Phe8,Sar9] Substance P (5-11) also increases motor activity and induces recovery of addictive agent-seeking behavior in rats.
体内研究：
[Glp5, (Me)Phe8,Sar9] Substance P (5-11) (注入腹侧被盖区；2 μg/侧；单次) 选择性地激活大鼠大脑间脑和中脑皮层的多巴胺代谢。[Glp5, (Me)Phe8,Sar9] Substance P (5-11) (注入腹侧被盖区；0.5、1.5、3 μg/侧；单次) 增加大鼠运动活性，诱导成瘾剂寻求行为的恢复。Animal Model:Male Sprague-Dawley rats (300-350 g).
Dosage:2 μg/side
Administration:Inject into the ventral tegmental area; single
Result:Selectively activated mesolimbic and mesocortical dopamine metabolism.
Animal Model:Male Wistar rats (300-350 g).
Dosage:0.5, 1.5, 3 μg/side
Administration:Inject into the ventral tegmental area; single
Result:Significantly increased locomotor activity when at 3 μg/side.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备